Akums Drugs & Pharmaceuticals Ltd (AKUMS)
₹731.70
Mkt cap
₹11,517 Cr
P/E ratio
37.80
P/B
3.47
Div yield
0.14%
ROE
8.45%
ROCE
14.90%
EPS (TTM)
₹19.36
Book value
₹211
52W range
409–839
Sector
Healthcare
Price history
Previous close
Established in 2004, Akums Drugs and Pharmaceuticals Limited is a pharmaceutical contract development and manufacturing organization (CDMO) offering a comprehensive range of pharmaceutical products and services. [1]
NSE AKUMSBSE 544222
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−12.77% from high₹732
₹409+78.77% from low₹839
Current
₹731.70
Prev close
₹741.05
Day
−1.26%
Price performance
1D
−0.82%
1W
+9.87%
1M
−10.32%
3M
+11.26%
6M
+35.18%
1Y
+58.73%
YTD
+61.93%
Financials
Revenue, profit & margin
P/E ratio
37.8×
AKUMS is 10% above the sector median of 34.4×
AKUMS37.8×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 970 | 1,181 | 1,083 | 944 | 1,019 | 1,033 | 1,010 | 1,056 | 1,024 | 1,018 | 1,160 | 1,158 | 1,167 | |
| Expenses | 1,095 | 1,029 | 989 | 941 | 891 | 912 | 889 | 962 | 895 | 923 | 1,013 | 1,006 | 992 | |
| Operating Profit | -125 | 152 | 93 | 3 | 128 | 121 | 121 | 94 | 129 | 94 | 147 | 152 | 175 | |
| OPM % | -13% | 13% | 9% | 0.3% | 13% | 12% | 12% | 9% | 13% | 9% | 13% | 13% | 15% | |
| Other Income | 8 | -21 | 10 | 10 | 7 | 17 | 19 | 26 | 27 | 32 | 16 | 34 | 30 | |
| Interest | 12 | 14 | 12 | 12 | 13 | 12 | 5 | 5 | 23 | 23 | 24 | 24 | 25 | |
| Depreciation | 30 | 30 | 32 | 34 | 34 | 35 | 45 | 40 | 37 | 38 | 40 | 40 | 41 | |
| Profit before tax | -159 | 87 | 59 | -33 | 87 | 92 | 91 | 75 | 96 | 66 | 100 | 121 | 139 | |
| Tax % | 18% | 62% | -229% | 20% | 30% | 27% | 27% | -99% | 32% | 35% | 32% | 33% | 27% | |
| Net Profit | -187 | 33 | 195 | -39 | 61 | 67 | 66 | 150 | 65 | 43 | 68 | 81 | 101 | |
| EPS in Rs | -13.16 | 2.22 | 13.54 | -2.89 | 4.08 | 4.14 | 4.14 | 9.38 | 4.03 | 2.59 | 4.21 | 5.38 | 6.35 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
2 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
No reaction history yet.
No quarterly filings ingested yet.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202675.26%Promoter
Promoters75.26%
FIIs4.50%2.59
DIIs11.09%2.35
Public6.42%0.25
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Akums Drugs | ₹731.70 | 37.75 | 11,517 | 0.14% | 101 | +57.55% | 1,167 | +13.93% | 14.94% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports2
Concall transcripts24
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026TranscriptFeb 2026PPTFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025TranscriptNov 2024PPTNov 2024TranscriptSep 2024PPTSep 2024RECSep 2024RECNov 2023
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 28 Oct - Intimation of Schedule of the Investors/Analysts Conference Call (group meet) for un-audited financial results of Q2 FY 2026-27Board Meeting Intimation for Intimation Of Board Meeting 28 Oct - Board meets November 2, 2026 to approve Q2 and half-year FY27 unaudited results.Intimation Under Regulation 30 Of The SEBI (LODR) Regulations, 2015 - Demand Notice 15 Oct - NPPA issued Rs 52.75 crore demand notice over Lanol 1000 mg injection pricing violation.Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 9 Oct - Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018Closure of Trading Window 25 Sep